Understand the Lives of People with Lupus and Launch a Product that Truly Fits Their Needs
Lupus is a complex disease with diverse manifestations, limited treatment options and inequitable impact on the affected population. This makes research into patient experience, treatment patterns, and long-term clinical outcomes particularly challenging.
At Alira Health, we have developed specialized expertise in lupus, aiding companies in addressing unmet lupus patient needs. Our aim is to drive innovation in this challenging area, especially in underserved segments and communities.
Registry data serves as a valuable resource to unlock insights and accelerate research in lupus. Comprehensive, de-identified, and complete clinical and patient experience data at your fingertips — thanks to the collaboration between Alira Health and FORWARD, the National Databank for Rheumatic Diseases — in the largest patient-reported research databank for rheumatic disorders in the US.
6,000+ lupus patients have participated in at least one survey*
*Surveys include questions relating to symptoms of systemic lupus, cutaneous lupus, and lupus nephritis
3,000+ patients with a self-reported or MD-confirmed SLE diagnosis
2,000+ patients with MD-confirmed SLE diagnosis
5 years average duration of follow-up
The lupus registry is an open cohort. Enrollment and follow-up remains active and ongoing.
How can you translate the insights of the lupus patient journey into value-added takeaways for your lupus asset? Watch on-demand!
We’re committed to fostering innovation and bridging the gap between observational and interventional research in lupus to ensure data accurately reflects patients’ real-life experiences.
Partner with us to benefit from:
Despite significant advances in fit-for-purpose real-world evidence on the epidemiology, economic and humanistic burden, and disease trajectory of lupus, outcomes of patients with lupus remain scarce. This hinders the ability to measure the impact of early intervention and innovative treatment strategies targeted at clinical remission or low disease activity. To change this, we are developing connected digital solutions and partnering with patient groups and clinical experts because we believe in working with the participation of patients for the benefit of patients.
Working with patients on lupus solutions is crucial due to the unique, complex, and challenging journey they face. At Alira Health, we are committed to elevating the voices of those affected by lupus, ensuring they are equal partners in the development of treatments. Through strategic patient engagement and access to real patient insights, we help our clients gain invaluable understanding of the lives of people with lupus and assist in launching solutions that truly meet patients’ needs.
Lupus poses ongoing challenges in both diagnosis and treatment. It has diverse manifestations, limited treatment options and inequitable impact on the affected populations. This makes research into patient experience, treatment patterns, and long-term clinical outcomes particularly challenging. We are excited to help companies increase awareness of this complex disease, expand research efforts, and improve access to care.
RWD provides insight into the effectiveness, safety, and usage of new treatments, beyond what is typically determined in the clinical trial process. Explore the benefits of RWD in lupus, the value of leveraging RWD throughout the lupus product lifecycle, and the RWD sources available in this indication.
If you would like to learn more about NLP for the analysis of complex diseases like Lupus, check out this summary of our poster, “Harnessing the potential of natural-language processing and interconnected data streams for complex diseases in the hospital setting: Lupus case study in France,” presented at ISPOR Europe 2023.
